Literature DB >> 23760626

Serum sTWEAK concentrations and risk of developing type 2 diabetes in a high cardiovascular risk population: a nested case-control study.

Andrés Díaz-López1, Matilde R Chacón, Mònica Bulló, Elsa Maymó-Masip, Miguel A Martínez-González, Ramón Estruch, Joan Vendrell, Josep Basora, Javier Díez-Espino, María-Isabel Covas, Jordi Salas-Salvadó.   

Abstract

CONTEXT AND
OBJECTIVE: Because serum concentrations of soluble forms of TNF-like weak inducer of apoptosis (sTWEAK) and scavenger receptor CD163 (sCD163) have been associated with insulin resistance and type 2 diabetes mellitus (T2D), we tested the associations of sTWEAK and sCD163 with the future development of T2D in elderly subjects at high cardiovascular risk. DESIGN, SETTING, AND PARTICIPANTS: A prospective, matched case-control study of 153 cases of newly diagnosed diabetic subjects and 306 individually matched controls who did not develop diabetes during a mean 5-year follow-up was conducted using data from the PREDIMED study. Conditional logistic regression was used to estimate the matched odds ratio (OR) for incident T2D according to categories of baseline sTWEAK and sCD163 concentrations measured by ELISA.
RESULTS: Baseline sTWEAK concentrations were lower in cases than controls. There were no case-control differences in sCD163 concentrations. In the conditional logistic model that took into account the matching factors, the ORs for T2D incidence in the highest vs the lowest quartile of sTWEAK and the sCD163/sTWEAK ratio were 0.49 (95% confidence interval [CI], 0.31-0.76; P for trend <.01) and 1.67 (95% CI, 1.06-2.63; P for trend = .05), respectively. Further adjustment for potential lifestyle confounding factors had little impact on these estimates, whereas adjustment for metabolic syndrome components and fasting insulin levels attenuated the magnitude of associations and only the sTWEAK remained statistically significant (OR = 0.63; 95% CI, 0.40-0.98; P for trend = .05).
CONCLUSION: These findings indicate that in a population at high cardiovascular risk, reduced circulating levels of sTWEAK are associated with an increased risk of diabetes incidence.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23760626     DOI: 10.1210/jc.2013-1848

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  12 in total

1.  Reduced circulating levels of sTWEAK are associated with NAFLD and may affect hepatocyte triglyceride accumulation.

Authors:  J Lozano-Bartolomé; G Llauradó; M M Rodriguez; J M Fernandez-Real; J F Garcia-Fontgivell; J Puig; E Maymó-Masip; J Vendrell; M R Chacón
Journal:  Int J Obes (Lond)       Date:  2016-04-28       Impact factor: 5.095

2.  Reduced circulating sTWEAK levels are associated with metabolic syndrome in elderly individuals at high cardiovascular risk.

Authors:  Andrés Díaz-López; Mònica Bulló; Matilde R Chacón; Ramón Estruch; Joan Vendrell; Javier Díez-Espino; Montserrat Fitó; Dolores Corella; Jordi Salas-Salvadó
Journal:  Cardiovasc Diabetol       Date:  2014-02-24       Impact factor: 9.951

Review 3.  TWEAK: A New Player in Obesity and Diabetes.

Authors:  Joan Vendrell; Matilde R Chacón
Journal:  Front Immunol       Date:  2013-12-30       Impact factor: 7.561

Review 4.  Clinical significance of sCD163 and its possible role in asthma (Review).

Authors:  Yue Zhi; Peng Gao; Xiuqin Xin; Wei Li; Lei Ji; Lin Zhang; Xueyang Zhang; Jie Zhang
Journal:  Mol Med Rep       Date:  2017-03-24       Impact factor: 2.952

Review 5.  TRAIL, OPG, and TWEAK in kidney disease: biomarkers or therapeutic targets?

Authors:  Stella Bernardi; Rebecca Voltan; Erika Rimondi; Elisabetta Melloni; Daniela Milani; Carlo Cervellati; Donato Gemmati; Claudio Celeghini; Paola Secchiero; Giorgio Zauli; Veronica Tisato
Journal:  Clin Sci (Lond)       Date:  2019-05-16       Impact factor: 6.124

6.  The effect of resveratrol supplementation on the expression levels of factors associated with cellular senescence and sCD163/sTWEAK ratio in patients with type 2 diabetes mellitus: study protocol for a double-blind controlled randomised clinical trial.

Authors:  Shima Abdollahi; Amin Salehi-Abargouei; Mahtab Tabatabaie; Mohammad Hasan Sheikhha; Hossein Fallahzadeh; Masoud Rahmanian; Omid Toupchian; Elham Karimi-Nazari; Hassan Mozaffari-Khosravi
Journal:  BMJ Open       Date:  2019-07-04       Impact factor: 2.692

7.  Circulating sTweak is associated with visceral adiposity and severity in patients with obstructive sleep apnea syndrome.

Authors:  Sule Cilekar; Selvihan Beysel; Savas Karatas; Aydin Balci; Kursad Akaslan; Ali Uncu
Journal:  Sci Rep       Date:  2021-11-11       Impact factor: 4.379

Review 8.  Role of the TWEAK-Fn14-cIAP1-NF-κB Signaling Axis in the Regulation of Myogenesis and Muscle Homeostasis.

Authors:  Emeka K Enwere; Eric C Lacasse; Nadine J Adam; Robert G Korneluk
Journal:  Front Immunol       Date:  2014-02-05       Impact factor: 7.561

9.  Serum sCD163 levels are associated with type 2 diabetes mellitus and are influenced by coffee and wine consumption: results of the Di@bet.es study.

Authors:  Gemma Rojo-Martínez; Elsa Maymó-Masip; M Mar Rodríguez; Esther Solano; Albert Goday; Federico Soriguer; Sergio Valdés; Felipe Javier Chaves; Elías Delgado; Natalia Colomo; Pilar Hernández; Joan Vendrell; Matilde R Chacón
Journal:  PLoS One       Date:  2014-06-30       Impact factor: 3.240

10.  Clinical significance of serum interleukin-8 and soluble tumor necrosis factor-like weak inducer of apoptosis levels in patients with diabetic nephropathy.

Authors:  Shu-Yan Liu; Jie Chen; Yong-Feng Li
Journal:  J Diabetes Investig       Date:  2018-03-26       Impact factor: 4.232

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.